179 related articles for article (PubMed ID: 30315613)
1. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan.
Okabe A; Hayashi H; Maeda H
Curr Oncol; 2023 Feb; 30(2):1776-1783. PubMed ID: 36826098
[TBL] [Abstract][Full Text] [Related]
3. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
4. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
[TBL] [Abstract][Full Text] [Related]
5. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
6. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
7. [Efficiency of oncologic treatments for solid tumours in Spain].
Oyagüez I; Frías C; Seguí MÁ; Gómez-Barrera M; Casado MÁ; Queralt Gorgas M
Farm Hosp; 2013; 37(3):240-59. PubMed ID: 23789801
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy.
Shibata S; Matsushita M; Saito Y; Suzuki T
Ther Innov Regul Sci; 2018 Nov; 52(6):718-723. PubMed ID: 29714569
[TBL] [Abstract][Full Text] [Related]
9. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
10. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Pinto A; Naci H; Neez E; Mossialos E
Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
[TBL] [Abstract][Full Text] [Related]
11. An expanded portfolio of survival metrics for assessing anticancer agents.
Karweit J; Kotapati S; Wagner S; Shaw JW; Wolfe SW; Abernethy AP
Am J Manag Care; 2017 Jan; 23(1):54-61. PubMed ID: 28141932
[TBL] [Abstract][Full Text] [Related]
12. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
13. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
14. Progression-free survival in oncology: Caveat emptor!
Bergmann TK; Christensen MMH; Henriksen DP; Haastrup MB; Damkier P
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):240-244. PubMed ID: 30417586
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
16. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
19. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
20. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
